BridgeBio Oncology Therapeutics, Inc. Operating Income
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Operating Income of -$60.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$60.19M.
- BridgeBio Oncology Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$46.18M.
- BridgeBio Oncology Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$43.41M.
- BridgeBio Oncology Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$49.18M.
- BridgeBio Oncology Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$41.69K.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$60.19M 10-Q · filed 2026-08-11 | -$106.37M 10-Q · filed 2026-08-11 | -$149.77M derived: sum of 3 quarters · filed 2026-08-11 | -$198.96M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$46.18M 10-Q · filed 2026-05-12 | -$89.59M derived: sum of 2 quarters · filed 2026-05-12 | -$138.77M derived: sum of 3 quarters · filed 2026-05-12 | -$168.86M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$43.41M 8-K · filed 2026-03-05 | -$92.59M derived: sum of 2 quarters · filed 2026-03-05 | -$122.68M derived: sum of 3 quarters · filed 2026-08-11 | -$145.82M POS AM · filed 2026-04-30 | ||||
| 2025-09-30 | -$49.18M 10-Q · filed 2025-11-12 | -$79.27M derived: sum of 2 quarters · filed 2026-08-11 | -$102.41M 10-Q · filed 2025-11-12 | -$124.29M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$30.09M 10-Q · filed 2026-08-11 | -$1.12M 10-Q · filed 2025-08-01 | -$53.23M 10-Q · filed 2026-08-11 | -$3.54M 10-Q · filed 2025-08-01 | -$75.11M derived: sum of 3 quarters · filed 2026-08-11 | -$94.77M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | -$23.14M 10-Q · filed 2026-05-12 | -$2.42M 10-Q · filed 2025-05-15 | -$45.02M derived: sum of 2 quarters · filed 2026-05-12 | -$64.68M derived: sum of 3 quarters · filed 2026-05-12 | -$64.83M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | -$21.88M 8-K · filed 2026-03-05 | -$41.54M derived: sum of 2 quarters · filed 2026-03-05 | -$41.70M derived: sum of 3 quarters · filed 2026-03-05 | -$80.86M POS AM · filed 2026-04-30 | -$584.39K 10-K · filed 2025-03-11 | |||
| 2024-09-30 | -$19.66M 10-Q · filed 2025-11-12 | -$146.85K 10-Q · filed 2024-11-14 | -$19.82M derived: sum of 2 quarters · filed 2025-11-12 | -$58.98M 10-Q · filed 2025-11-12 | -$365.90K 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | -$152.34K 10-Q · filed 2025-08-01 | -$219.04K 10-Q · filed 2025-08-01 | ||||||
| 2024-03-31 | -$66.70K 10-Q · filed 2025-05-15 | |||||||
| 2023-12-31 | -$41.69K 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |